Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

Autor: Maria Eugenia Fernández-Santos, Mariano Garcia-Arranz, Enrique J. Andreu, Ana Maria García-Hernández, Miriam López-Parra, Eva Villarón, Pilar Sepúlveda, Francisco Fernández-Avilés, Damian García-Olmo, Felipe Prosper, Fermin Sánchez-Guijo, Jose M. Moraleda, Agustin G. Zapata

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

MSCs products as well as their derived extracellular vesicles, are currently being explored as advanced biologics in cell-based therapies with high expectations for their clinical use in the next few years. In recent years, various strategies designe

Externí odkaz: https://doaj.org/article/859113e2a67f49de8a632985ba59dbc7

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

Autor: Fermín Sánchez-Guijo, Mariano García-Arranz, Miriam López-Parra, Pablo Monedero, Carmen Mata-Martínez, Arnoldo Santos, Víctor Sagredo, José-Manuel Álvarez-Avello, José Eugenio Guerrero, César Pérez-Calvo, Miguel-Vicente Sánchez-Hernández, José Luis Del-Pozo, Enrique J. Andreu, María-Eugenia Fernández-Santos, Barbara Soria-Juan, Luis M. Hernández-Blasco, Etelvina Andreu, José M. Sempere, Agustín G. Zapata, José M. Moraleda, Bernat Soria, Francisco Fernández-Avilés, Damián García-Olmo, Felipe Prósper

Publikováno v: EClinicalMedicine, Vol 25, Iss , Pp 100454- (2020)

Background: Identification of effective treatments in severe cases of COVID-19 requiring mechanical ventilation represents an unmet medical need. Our aim was to determine whether the administration of adipose-tissue derived mesenchymal stromal cells

Externí odkaz: https://doaj.org/article/01715df0f5f44ffc95be488bfb47c780

Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

Autor: Alejandro Gonzalez, Franz Martín, Antonio de la Cuesta Diaz, Fermín Sánchez-Guijo, César Aparicio, Manuel Miralles, Eva Villarón, Miriam Lopez Parra, María Eugenia Fernández-Santos, Barbara Soria-Juan, José Manuel Ligero, Abdelkrim Hmadcha, Bernat Soria, José M. Moraleda, Francisco S. Lozano, Mariano Garcia-Arranz, Rosa Yañez, Pedro J. Marín, Luis Hernandez-Blasco, Ignacio Mahillo Fernández, Ana M García-Hernández, Francisco J. Bedoya, Enrique J. Andreu, Lourdes Del Rio Sola, Juan R. Tejedo, Etelvina Andreu, Lukasz Grochowicz, Gregorio Castellanos, Lucía Llanos Jiménez, Luis Riera del Moral, Damian Garcia-Olmo, Francisco Morant

Publikováno v: Trials
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Background Chronic lower limb ischemia develops earlier and more frequently in patients with type 2 diabetes mellitus. Diabetes remains the main cause of lower-extremity non-traumatic amputations. Current medical treatment, based on antiplatelet ther

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa8d192b7c607777f41d03ff9a19dc05
https://doi.org/10.1186/s13063-021-05430-2

Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial

Autor: Fermín Sánchez-Guijo, Enrique J. Andreu, Juan P. de-Torres, Rosa Cordovilla, Arantza Campo, Eva Villarón, José María González-Ruiz, Miguel Barrueco, Maria del Mar Ocon, Jesus Pueyo, Jorge M. Núñez-Córdoba, Ana B. Alcaide, Javier J. Zulueta, Felipe Prosper

Publikováno v: ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research, Vol 7, Iss 2 (2021)

Rationale Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases. Objectives To evaluate the safety and feasibility of endobronchial administration of bone marrow

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4ef0d6d8cf06f73bfc9a04e1f94825
http://europepmc.org/articles/PMC8236617

Preclinical Evaluation of the Safety and Immunological Action of Allogeneic ADSC-Collagen Scaffolds in the Treatment of Chronic Ischemic Cardiomyopathy

Autor: Francisco M. Sánchez-Margallo, Ascensión López-Díaz de Cerio, Beatriz Pelacho, Saray Rodriguez, Enrique J. Andreu, Verónica Crisóstomo, Susana Inogés, Francisco Fernández-Avilés, Gloria Abizanda, Inigo Perez-Estenaga, Ana Gloria Gil, Javier Bermejo, Lluis Quintana, Juan José Gavira, Eduardo Larequi, Blanca Jauregui, Felipe Prosper

Publikováno v: E-Prints Complutense. Archivo Institucional de la UCM
instname
Pharmaceutics, Vol 13, Iss 1269, p 1269 (2021)
Pharmaceutics
Volume 13
Issue 8

The use of allogeneic adipose-derived mesenchymal stromal cells (alloADSCs) represents an attractive approach for treating myocardial infarction (MI). Furthermore, adding a natural support improves alloADSCs engraftment and survival in heart tissues,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41b4db9bb629c238ad62658162b68d3c
https://eprints.ucm.es/id/eprint/71827/1/pharmaceutics-13-01269.pdf